[go: up one dir, main page]

CN110997637A - 芳香类衍生物、其制备方法及其在医药上的应用 - Google Patents

芳香类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN110997637A
CN110997637A CN201880034411.9A CN201880034411A CN110997637A CN 110997637 A CN110997637 A CN 110997637A CN 201880034411 A CN201880034411 A CN 201880034411A CN 110997637 A CN110997637 A CN 110997637A
Authority
CN
China
Prior art keywords
independently selected
group
alkyl
dimethoxyphenyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880034411.9A
Other languages
English (en)
Other versions
CN110997637B (zh
Inventor
邵宁
王丁
袁宏斌
弗兰克.凯泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bosgene Biotechnology Shanghai Co ltd
Original Assignee
Boaades Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boaades Biotech filed Critical Boaades Biotech
Publication of CN110997637A publication Critical patent/CN110997637A/zh
Application granted granted Critical
Publication of CN110997637B publication Critical patent/CN110997637B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种通式(I)所示的芳香类衍生物及其可药用的盐或含有其的药物组合物、及其制备方法，以及上述芳香类衍生物及其可药用的盐或含有其的药物组合物在制备治疗剂，特别是FGFR4酪氨酸激酶抑制剂，和在制备治疗和/或预防肿瘤与炎症等疾病的药物中的用途。其中通式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201880034411.9A 2017-09-05 2018-09-04 芳香类衍生物、其制备方法及其在医药上的应用 Active CN110997637B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017107912331 2017-09-05
CN201710791233 2017-09-05
PCT/CN2018/104007 WO2019047826A1 (zh) 2017-09-05 2018-09-04 芳香类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN110997637A true CN110997637A (zh) 2020-04-10
CN110997637B CN110997637B (zh) 2022-09-27

Family

ID=65634601

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034411.9A Active CN110997637B (zh) 2017-09-05 2018-09-04 芳香类衍生物、其制备方法及其在医药上的应用

Country Status (10)

Country Link
US (1) US11279697B2 (zh)
EP (1) EP3680236A4 (zh)
JP (2) JP7346420B2 (zh)
KR (1) KR102677016B1 (zh)
CN (1) CN110997637B (zh)
CA (1) CA3074885A1 (zh)
PH (1) PH12020500436A1 (zh)
SG (1) SG11202001979PA (zh)
TW (1) TWI817955B (zh)
WO (1) WO2019047826A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
WO2021060307A1 (ja) * 2019-09-25 2021-04-01 富士フイルム株式会社 イミダゾピリジン化合物またはその塩および医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540809A (zh) * 2012-07-11 2015-04-22 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US20160136168A1 (en) * 2013-07-18 2016-05-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer
CN105658642A (zh) * 2013-10-25 2016-06-08 蓝图药品公司 纤维母细胞生长因子受体抑制剂
WO2016134294A1 (en) * 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
AR098048A1 (es) 2013-10-18 2016-04-27 Eisai R&D Man Co Ltd Inhibidores de fgfr4
TR201810944T4 (tr) 2013-10-25 2018-08-27 Novartis Ag Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri.
PT3160935T (pt) 2014-06-24 2022-01-27 Covestro Intellectual Property Gmbh & Co Kg Processo para a produção de diaminas e poliaminas da gama difenilmetano
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906630B (zh) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
CN109224235B (zh) 2018-10-23 2020-05-19 孙喜家 一种双腔管
CN109331654A (zh) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 一种有机废气光催化氧化装置

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104540809A (zh) * 2012-07-11 2015-04-22 蓝印药品公司 成纤维细胞生长因子受体的抑制剂
US20160136168A1 (en) * 2013-07-18 2016-05-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer
CN105658642A (zh) * 2013-10-25 2016-06-08 蓝图药品公司 纤维母细胞生长因子受体抑制剂
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016134294A1 (en) * 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2016164703A1 (en) * 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBIN A. FAIRHURST 等: "Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATPpocket middle-hinge region", 《MEDCHEMCOMM》 *

Also Published As

Publication number Publication date
KR20200083448A (ko) 2020-07-08
KR102677016B1 (ko) 2024-06-19
EP3680236A1 (en) 2020-07-15
US11279697B2 (en) 2022-03-22
EP3680236A4 (en) 2021-04-21
PH12020500436A1 (en) 2021-02-08
TWI817955B (zh) 2023-10-11
WO2019047826A1 (zh) 2019-03-14
SG11202001979PA (en) 2020-04-29
TW201912631A (zh) 2019-04-01
CA3074885A1 (en) 2019-03-14
JP2020532581A (ja) 2020-11-12
CN110997637B (zh) 2022-09-27
JP2023158113A (ja) 2023-10-26
JP7346420B2 (ja) 2023-09-19
US20200262827A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
ES2316546T3 (es) 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
KR102058366B1 (ko) 축합 피리미딘 화합물 또는 그의 염
CN102131801B (zh) 1,2-二取代的杂环化合物
TWI433845B (zh) 嗒酮衍生物
TW201833108A (zh) 醯胺類衍生物抑制劑及其製備方法和應用
DE102008052943A1 (de) Azaindolderivate
KR102847070B1 (ko) 아자비시클릭 치환된 옥사스피로 유도체, 이의 제조 방법 및 의학적 용도
CN111434662B (zh) 卤代烯丙基胺类化合物及其应用
DE102008028905A1 (de) 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
WO2023216910A1 (zh) 取代的双环杂芳基化合物作为usp1抑制剂
EP3904355B1 (en) Substituted fused aromatic ring derivative, composition and use thereof
WO2018072707A1 (zh) 芳香族醚类衍生物、其制备方法及其在医药上的应用
JP2023158113A (ja) 芳香族誘導体、その調製方法、およびその医学的適用
CN108602807A (zh) 杂环磺酰胺衍生物及含有其的药物
HK40020552A (zh) 芳香类衍生物、其制备方法及其在医药上的应用
HK40020552B (zh) 芳香类衍生物、其制备方法及其在医药上的应用
JP5643192B2 (ja) 腫瘍を処置するためのチロシンキナーゼモジュレーターとしてのジヒドロピラゾール誘導体
CN116969944A (zh) 乙氨基取代的三环杂环化合物及其组合物、制剂和用途
KR20100065171A (ko) 티아디아지논 유도체
JP2023504730A (ja) Ｎ－（３－（５－（ピリミジン－４－イル）チアゾール－４－イル）フェニル）スルホンアミド化合物及びｂｒａｆ阻害剤としてのそれらの使用
WO2021114691A1 (zh) 含氮并环化合物、其制备方法及用途
CN112625025B (zh) 吡啶基取代的喹啉类衍生物及其制备方法和用途
DE102008062825A1 (de) 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
TWI727152B (zh) 炔代雜環化合物、其製備方法及其在醫藥學上的應用
CN118772141A (zh) 用于治疗癌症的DNA聚合酶Theta抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200423

Address after: Room 307, No.199, GuoShouJing Road, China (Shanghai) pilot Free Trade Zone, Pudong New Area, Shanghai

Applicant after: Bosgene Biotechnology (Shanghai) Co.,Ltd.

Address before: California, USA

Applicant before: Boaades biotech

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20200410

Assignee: Beijing shengnuoji Pharmaceutical Technology Co.,Ltd.

Assignor: Bosgene Biotechnology (Shanghai) Co.,Ltd.

Contract record no.: X2020990000449

Denomination of invention: Aromatic derivatives, their preparation methods and their application in medicine

License type: Exclusive License

Record date: 20200824

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020552

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant